Saturday 17 October 2026
Export CATX’s income statement to Excel — free account
Perspective Therapeutics, Inc.
CATX Healthcare Medical Devices
Perspective Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $884,000.00, down 39.2% from fiscal 2024. In the quarter to June 2026, revenue fell 72.1%, EPS grew 24.1%, free cash flow fell 66.1% and total debt fell 3.57%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.17
0.17
−7.26%
Follow CATX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1,005.92 | 699.08 | 229.62 | 237.06 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(19.92) | (13.73) | (8.23) | (15.64) | |
P/B ratio |
1.27 | 1.24 | 0.98 | 1.05 | |
Price to Tangible BV |
1.45 | 1.41 | 1.22 | 1.33 | |
EV/Sales |
430.52 | 263.19 | 67.67 | 76.54 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.89) | (1.76) | (0.73) | (0.97) | |
EV/FCF |
(1.45) | (1.52) | (0.63) | (0.77) | |
Quick Ratio |
6.49 | 8.61 | 5.05 | 8.45 | |
Current Ratio |
6.61 | 8.75 | 5.17 | 8.66 | |
Net Debt/EBITDA |
8.18 | 9.74 | 3.65 | 6.24 | |
Debt/Assets |
0.39% | 0.38% | 0.59% | 0.54% | |
Debt/Equity |
0.00 | 0.00 | 0.01 | 0.01 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 1.20 | 0.66 | 0.63 | |
Capex/Depreciation |
(29.57) | (10.78) | (8.31) | (9.18) | |
Interest Coverage |
(412.08) | (269.34) | (622.37) | (428.63) | |
Research and Development Expense of Revenue |
26,597.53% | 28,121.05% | 76,567.44% | 9,731.58% | |
Selling, General and Administrative Expense of Revenue |
9,623.46% | 9,190.79% | 16,165.12% | 3,699.04% | |
Intangible Assets out of Total Assets |
0.10 | 0.10 | 0.15 | 0.17 | |
Share Based Compensation of Revenue |
3,760.49% | 3,359.21% | 5,369.77% | 1,031.58% | |
Graham Net Nets |
0.42 | 0.49 | 0.44 | 0.49 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(38.91%) | (33.50%) | (50.80%) | (43.23%) | |
Free Cash Flow Yield |
(29.46%) | (24.84%) | (46.92%) | (41.75%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.17) | (0.30) | (0.33) | (0.22) | |
Capex per Share |
(0.12) | (0.07) | (0.07) | (0.03) | |
Free Cash Flow per Share |
(0.29) | (0.37) | (0.40) | (0.25) | |
Cash per Share |
1.96 | 2.62 | 1.96 | 2.34 | |
Shareholders Equity per Share |
2.68 | 3.35 | 2.80 | 3.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.68 | 3.35 | 2.80 | 3.26 | |
Free Cash Flow |
(34.84) | (38.33) | (29.73) | (18.28) | |
Working Capital |
204.98 | 243.87 | 119.71 | 157.88 | |
Capital Expenditures |
(14.19) | (6.86) | (5.07) | (1.99) | |
Net Current Asset Value |
173.36 | 212.02 | 88.45 | 125.89 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
175.25 | 90.24 | 118.02 | 9.53 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.25 | 0.07 | 0.06 | 0.20 | |
Average Payables |
18.23 | 17.61 | 15.43 | 17.48 | |
Average Assets |
351.38 | 370.06 | 304.04 | 342.99 | |
Average Common Equity |
294.78 | 316.04 | 248.85 | 285.34 |
Columns are period end dates